Living donor liver transplantation in patients with hepatitis C.
1. Hepatitis C virus (HCV) is the most common indication for living donor liver transplantation (LDLT). 2. Preliminary evidence suggests that HCV may occur earlier and may be more severe in LDLT recipients. However, current data is inconclusive relative to the impact of recurrent HCV on patient and graft survival in LDLT recipients. 3. Potential mechanisms for differences in severity of HCV in LDLT recipients are discussed. 4. LDLT remains a viable treatment option for selected patients with HCV.
Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver, CO 80202, USA.
Michael A
MA
Zimmerman
James F
JF
Trotter
D000998:Antiviral Agents / Q000008:administration & dosage; D006085:Graft Survival / Q000502:physiology; D006526:Hepatitis C / Q000601:surgery*; D006801:Humans; D007165:Immunosuppression Therapy; D008099:Liver / Q000276:immunology / Q000821:virology; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000276:immunology; D019520:Living Donors; D011184:Postoperative Period; D012008:Recurrence
D000998:Antiviral Agents